Background/Aims Given the increase in prevalence of metabolic diseases, we investigated their long-term impacts on the outcomes of chronic hepatitis B (CHB) patients receiving nucleos(t)ide analogue (NA) treatment.
Methods We analyzed data from CHB patients for whom initiated NA treatment from 30 centers. We balanced patient characteristics with and without metabolic disease (diabetes, obesity, dyslipidemia, and hypertension) via propensity-score matching (PSM) to evaluate adverse outcomes.
Results The study included 4,500 patients. PSM yielded 909 pairs of patients with balanced characteristics. When stratified by the number of metabolic diseases, only patients with ≥2 metabolic diseases had an increased cumulative incidence of cirrhosis and overall death. However, when stratified by the presence of diabetes (regardless of the presence or number of other metabolic diseases), patients with diabetes (versus those without) had a significantly higher cumulative incidence of all outcomes: cirrhosis (P=0.009), hepatocellular carcinoma (HCC, P=0.023), and overall, liver-related, and non-liver-related death (P<0.001, P=0.026 and P<0.001, respectively). Having ≥2 metabolic diseases was associated with cirrhosis, overall death, and non-liver-related death but not HCC or liver-related death, while diabetes was significantly associated with a higher risk of all outcomes: cirrhosis (hazard ratio [HR]=3.75, P=0.004), HCC (HR=2.02, P=0.020), and overall, liver-related, and non-liver-related death (HR=2.53, P<0.001; HR=2.65, P=0.016; HR=2.38, P<0.001).
Conclusions Having two or more metabolic diseases was associated with a higher risk of cirrhosis, overall death, and non-liver-related death, but having diabetes as a single metabolic disease was significantly associated with all adverse outcomes including cirrhosis, HCC, and overall, liver-related, and non-liver-related death.
Citations
Citations to this article as recorded by
Type 2 diabetes mellitus as an independent predictor of significant fibrosis in treatment-naïve chronic hepatitis B patients with concurrent hepatic steatosis Jie Li, Liang Xu, Fajuan Rui, Sally Tran, Pei-Chien Tsai, Youwen Tan, Hidenori Toyoda, Qing-Lei Zeng, Huy Trinh, Yao-Chun Hsu, Tsunamasa Watanabe, Hiroshi Abe, Hiroyuki Motoyama, Yoko Yoshimaru, Takanori Suzuki, Taeang Arai, Masanori Atsukawa, Phillip Vut Hepatology.2026; 83(5): 1273. CrossRef
Advancing metabolic risk profiling in chronic hepatitis B: Reply to correspondence on “Metabolic health in antiviral era of chronic hepatitis B” Shang-Chin Huang, Jia-Horng Kao Clinical and Molecular Hepatology.2026; 32(1): e117. CrossRef
Metabolic health in antiviral era of chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues” Shang-Chin Huang, Jia-Horng Kao Clinical and Molecular Hepatology.2026; 32(1): 423. CrossRef
Diagnosis and management of metabolic dysfunction-associated steatohepatitis in patients with chronic hepatitis B infection Talal K Bhatti, Joseph K Lim World Journal of Gastroenterology.2026;[Epub] CrossRef
Diabetes Impairs the Virological Response in Patients with Chronic Hepatitis B: Glycemic Control as a Key Modifiable Risk Factor Aoyi Li, Yan Han, Guanglin Xiao, Zhiling Deng, Chaojing Wen, Ke Qiu, Taiyu He, Hong Ren Journal of Clinical Medicine.2026; 15(5): 1826. CrossRef
Antiviral Therapy Reduces Hepatocellular Carcinoma and Cirrhosis Risk in Chinese Chronic Hepatitis B Patients With Mildly Elevated Alanine Aminotransferase Jian Wang, Zhiyi Zhang, Li Zhu, Tao Fan, Ye Xiong, Shaoqiu Zhang, Chao Jiang, Shengxia Yin, Xin Tong, Juan Xia, Xiaomin Yan, Renling Yao, Yu Shi, Xingxiang Liu, Chuanwu Zhu, Chao Wu, Rui Huang Clinical Gastroenterology and Hepatology.2026;[Epub] CrossRef
Steatosis paradox: Unraveling pathways of suppressive effect of hepatic steatosis on hepatitis B virus Shang-Chin Huang, Jia-Horng Kao Biomedical Journal.2026; 49(3): 100969. CrossRef
Impact of Cardiometabolic Risk Factors and Steatotic Liver Disease on Liver‐Related Outcomes in Patients With Chronic Hepatitis C After Curative Antiviral Therapy Chung‐Feng Huang, Yi‐Hung Lin, Pei‐Chien Tsai, Ming‐Lun Yeh, Chih‐Wen Wang, Tyng‐Yuan Jang, Po‐Cheng Liang, Yu‐Ju Wei, Nai‐Jen Hou, Ming‐Yen Hsieh, Chao‐Kuan Huang, Tzu‐Chun Lin, Jee‐Fu Huang, Chia‐Yen Dai, Wan‐Long Chuang, Ming‐Lung Yu The Kaohsiung Journal of Medical Sciences.2026;[Epub] CrossRef
Absence of steatosis combined with cardiometabolic risk factors confers the highest hepatocellular carcinoma risk in treated chronic hepatitis B Hung-Wei Wang, Hsueh-Chou Lai, Wei-Fan Hsu, Sheng-Hung Chen, Yi-Chun Kuo, Cheng-Yuan Peng Annals of Medicine.2026;[Epub] CrossRef
Diagnosing and defining MASLD in people living with chronic hepatitis B Emily Martyn, Alejandro Arenas-Pinto, Richard Gilson, Nomathemba Chandiwana, Stuart Flanagan, Douglas MacDonald, Emmanuel A. Tsochatzis, W. D. Francois Venter, Jennifer Manne-Goehler, Philippa C. Matthews Communications Medicine.2026;[Epub] CrossRef
The Chronic Hepatitis B and Metabolic Dysfunction-Associated Steatotic Liver Disease Paradox: Friend or Foe? Shang-Chin Huang, Tai-Chung Tseng Gut and Liver.2026; 20(3): 350. CrossRef
Insulin Resistance and Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients Under Antiviral Therapy Dong Hyun Sinn, Kyung-Ah Kim, Jung Il Lee, Geum-Youn Gwak Journal of Korean Medical Science.2026;[Epub] CrossRef
Efficacy and Safety of Switching from Entecavir to Tenofovir Alafenamide in Chronic Hepatitis B: A Multicenter Randomized Trial in Korea Hyunjae Shin, Moon Haeng Hur, Yang Hyun Baek, Chun Kyon Lee, Yong Kyun Cho, June Sung Lee, Jae Yoon Jeong, Yong Jin Jung, Ja Kyung Kim, Moon Young Kim, Yeon Seok Seo, Woo Jin Chung, Moon Soo Koh, Jeong-Han Kim, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Gut and Liver.2026; 20(4): 636. CrossRef
Comparable Predictive Performance of Non‐VCTE–Based Machine Learning Model for HBV‐Infected Hepatocellular Carcinoma Risk Hahn Yi, Hye Won Lee, Jae Il Shin, Hyung Woong Lee, Tae Seop Lim, Beom Kyung Kim, Namkug Kim Journal of Gastroenterology and Hepatology.2026;[Epub] CrossRef
Differential HCC risk among HBV indeterminate types at baseline and by phase transition Rui Huang, Huy N Trinh, Satoshi Yasuda, Angela Chau, Mayumi Maeda, Ai-Thien Do, Daniel Q Huang, Takanori Ito, Takashi Honda, Masatoshi Ishigami, Ritsuzo Kozuka, Carmen Monica Preda, Cheng-Hao Tseng, Sebastián Marciano, Pei-Chien Tsai, Dong Hyun Lee, Chris Gut.2025; 74(11): 1873. CrossRef
Incidence and determinants of achieving HBsAg <100 IU/mL in HBeAg-negative CHB patients with nucleos(t)ide analogue treatment Jian Wang, Tao Fan, Zhiyi Zhang, Li Zhu, Shaoqiu Zhang, Ye Xiong, Chun Shan, Chao Jiang, Shengxia Yin, Xin Tong, Renling Yao, Juan Xia, Xiaomin Yan, Yu Shi, Yuxin Chen, Xingxiang Liu, Huali Wang, Haixia Zhang, Chuanwu Zhu, Qun Zhang, Chao Wu, Rui Huang Emerging Microbes & Infections.2025;[Epub] CrossRef
Impact of metabolic dysfunction on treatment responses to nucleos(t)ide analogues in chronic hepatitis B: a retrospective multi-center REAL-B cohort study Rui Huang, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Huy Trinh, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Haruki Uojima, Daniel Q. Huang, Takashi Honda, Yasuhito Tanaka, Philip Vutien, Sebastián Marciano, Hiroshi Abe, Masaru Enomoto, Masanori Ats eClinicalMedicine.2025; 87: 103407. CrossRef
Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV‐Related Cirrhosis: A Landmark Analysis Mi Na Kim, Geun U. Park, Seng Chan You, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn Journal of Gastroenterology and Hepatology.2025; 40(11): 2750. CrossRef
Multifunctional Metal Composite Hydrogels for Diabetic Wound Therapy Shengnan Zhang, Hui Gao, Kevin H. Mayo, Jingang Mo, Le Deng Gels.2025; 11(12): 960. CrossRef
Liver fibrosis reflects tissue scarring in the liver due to the accumulation of excessive extracellular matrix in response to chronically persistent liver injury. Hepatocyte cell death can trigger capillarization of liver sinusoidal endothelial cells, stimulation of immune cells including macrophages and Kupffer cells, and activation of hepatic stellate cells (HSCs), resulting in progression of liver fibrosis. Liver cirrhosis is the terminal state of liver fibrosis and is associated with severe complications, such as liver failure, portal hypertension, and liver cancer. Nevertheless, effective therapy for cirrhosis has not yet been established, and liver transplantation is the only radical treatment for severe cases. Studies investigating HSC activation and regulation of collagen production in the liver have made breakthroughs in recent decades that have advanced the knowledge regarding liver fibrosis pathophysiology. In this review, we summarize molecular mechanisms of liver fibrosis and discuss the development of novel anti-fibrotic therapies.
Citations
Citations to this article as recorded by
Real-World Experience of Home Continuous Terlipressin Infusion for Complications of Portal Hypertension Brooke Chapman, Marie Sinclair, Avik Majumdar, Catherine Yu, James Widdop, Rudolf Hoermann, Kate Collins, Ryma Terbah, Katrina Tan, Adam Testro American Journal of Gastroenterology.2026; 121(5): 1132. CrossRef
Tetramethylpyrazine improves the structure and function of mitochondrial-associated endoplasmic reticulum membrane and liver fibrosis Kaihong Xie, Jianzhi Wu, Liping Gong, Wenqing Qin, Zixuan Huo, Yinhao Zhang, Jiaorong Qu, Runping Liu, Jianan Li, Jianhang Lan, Yufei Li, Ranyi Luo, Xiaojiaoyang Li Journal of Advanced Research.2026; 84: 1043. CrossRef
Roumudan decoction attenuates hepatic fibrosis by suppressing the Warburg effect via inhibiting key glycolytic proteins Meng Pan, Huanyu Li, Hao Guo, Shiting Luo, Jianxuan Yao, Mingxin Zhang, Yang Luo, Xiaoyan Shi Journal of Ethnopharmacology.2026; 356: 120862. CrossRef
Advanced strategies based on nanomedicine for Liver fibrosis treatment Lu Zhang, Tingting Liu, Huan Shen, Boheng Liu, Yun Mei, Yang Liu, Shuo Chen, Xingcong Ma, Chenyang He, Tinghua Hu, Bin Li, Gang Cao, Shuo Yu International Journal of Pharmaceutics.2026; 688: 126437. CrossRef
Salvianolic acid B targets MST1/2-YAP axis to drive phospho-Smad3L/C conversion against hepatocarcinogenesis Wenjing Xu, Yanyan Xu, Shuchen Han, Yuqi Dang, Changfeng Xue, Jingqi Zhou, Shufang He, Yongfang Gong, Yan Yang Phytomedicine.2026; 150: 157655. CrossRef
Modulating MiR-350/Akt/mTOR/beclin1 signaling by nitazoxanide ameliorates bleomycin-induced pulmonary fibrosis in a wistar rat model Eman M. Elbaz, Yara Shawky, Amina A.S. Abdel Rahman, Maha Abdelmonem Life Sciences.2026; 386: 124166. CrossRef
Immune System and Hepatic Stellate Cells’ Crosstalk in Liver Fibrosis: Pathways and Therapeutic Potential Wahyu Widowati, Adilah Hafizha Nur Sabrina, Annisa Firdaus Sutendi, Fadhilah Haifa Zahiroh, Aris Muhamad Nurjamil, Teresa Liliana Wargasetia, Ita Margaretha Nainggolan, Rizal Azis, Elham Rismani, Massoud Vosough, Poorani Gurumallesh Prabu Journal of Immunology Research.2026;[Epub] CrossRef
Hepatic Fibrosis and Liver Cancer Aina Anton, Scott L. Friedman, Bruno Cogliati Seminars in Liver Disease.2026; 46(01): 031. CrossRef
Salvianolic acid C attenuates liver fibrosis and inhibites hepatic stellate cell activation by targeting FAP/TβRI/SMAD axis Tao Sun, Xue Zheng, Liang Li, Jin Chu, Qiang Guo, Ning Yang, Xue Zhang, Xiaotong Li, Bowen Shi, Hongbin Zhang, Guodong Lü, Lufeng Cheng, Renyong Lin, Xiaojuan Bi International Immunopharmacology.2026; 175: 116400. CrossRef
Buyanghuanwu decoction (BYHWD) attenuates hepatic fibrosis in CCl4-induced mice by regulating bile acid metabolism through activating PPARα Xia Wei, Zikang Wang, Jiao Wang, Hailin Yang, Fengfeng Zhou, Shenglan Qi, Jianwei Zhang, Xiaoli Shi, Guanglin Xu, Zhengxin Li, Ying Xu, Dingqi Zhang Journal of Ethnopharmacology.2026; 364: 121476. CrossRef
Self-calibrating ultrasensitive biosensing platform based on multifunctional nanocomposites and DNAzyme-assisted CRISPR/Cas12a system for accurate TGF-β1 quantification in liver fibrosis assessment Lina Lu, Yaran Tao, Jiaxuan Qiao, Bingjun He, Yu Zhu, Fuju Dai, Tong Wang, Zhijie Wang, Xiangrui Wang, Yusheng Li, Jun Jiao, Lan Xue, Mengai Yin, Qiang Chen Chemical Engineering Journal.2026; 535: 175575. CrossRef
Mitochondrial Proteomics Uncovers that Myeloid S100A9 Deficiency Promotes Liver Injury and Fibrosis Regression via Mitochondrial Metabolic Reprogramming of Macrophages Jinfang Liu, Ruixi Liu, Yunwei Shi, Yi Sun, Zhenpeng Zhang, Mingsong Mao, Lei Chang, Tao Zhang, Chunguang Han, Junzhu Wu, Ping Xu Journal of Proteome Research.2026; 25(6): 2751. CrossRef
Mechanistic insights into the therapeutic potential of Andrographis paniculata against PFAS-induced hepatic fibrosis: an integrated strategy of network toxicology, pharmacology, and molecular docking Yulu Wang, Yudan Dong, Yifei Yang, Na Wang, Shuling Yu, Jintao Yuan Toxicology Research.2026;[Epub] CrossRef
Discovery of Jatrophane Diterpenoids as JAG1-Notch Signaling Inhibitors for the Treatment of Liver Fibrosis Xin-Ying Zhu, Shu-Qi Wu, Lu Gan, Xianyuan Yang, Yi-Ling Liao, Nan An, Run-Zhu Fan, Jia-Luo Huang, Gui-Hua Tang, Chuan-Rui Zhang, Sheng Yin Journal of Medicinal Chemistry.2026; 69(13): 15825. CrossRef
Protective effects of Astragaloside IV on various liver diseases: From chemistry to herbal medicines (Review) Jialu Shi, Xiaoyu Zhou, Jiabin Wu, Liru Zeng, Xia Wang, Wei Li, Xiao Huang, Xiaoyu Deng, Wenhong Wang International Journal of Molecular Medicine.2026; 58(3): 1. CrossRef
3D Liver Fibrosis Models in Lab: A Novel Modality for Drug Screening Hani Keshavarz Alikhani, Fatemeh Majidi, Mahsa Ghasemzad, Anastasia Shpichka, Anastasia Nestorova, Zahra Hendi, Elham Rismani, Daria Kuznetsova, Peter Timashev, Massoud Vosough, Abbas Piryaei Pharmacology Research & Perspectives.2026;[Epub] CrossRef
The Fibrosis-5 Index Predicts Major Adverse Cardiovascular Events in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention Senjiang Chen, Bouwei Zhu, Zan Luo, Yinchao Wang, Qingqing Hu, Liang Zhou Angiology.2025; 76(8): 734. CrossRef
Hepatic antifibrotic effects of bezafibrate in vitro and in vivo models of liver fibrosis Camille Kirinus Reghelin, Matheus Scherer Bastos, Bruno de Souza Basso, Bruna Pasqualotto Costa, Arieli Cruz de Sousa, Bianca Andrade Martha, Géssica Luana Antunes, Marcella Tornquist Nassr, Maria Claudia Rosa Garcia, Lucas Strassburger Matzenbacher, Vito Food and Chemical Toxicology.2025; 200: 115351. CrossRef
Multiomics Analysis and Machine Learning-based Identification of Molecular Signatures for Diagnostic Classification in Liver Disease Types Along the Microbiota-gut-liver Axis Betul Comertpay, Esra Gov Journal of Clinical and Experimental Hepatology.2025; 15(5): 102552. CrossRef
Challenges of in vitro modelling of liver fibrosis Patricia Ros-Tarraga, Estela Villanueva-Badenas, Estela Sanchez-Gonzalez, Gloria Gallego-Ferrer, M. Teresa Donato, Laia Tolosa Frontiers in Cell and Developmental Biology.2025;[Epub] CrossRef
Phosphocreatine alleviates liver fibrosis in diabetic mice by targeting TGF-β/Smad and α-SMA pathways Fu Han Wang, Eskandar Qaed, Waleed Aldahmash, Mueataz A. Mahyoub, Dalal Sanad Al-Mutairi, Zeyao Tang, Marwan almoiliqy Tissue and Cell.2025; 96: 103013. CrossRef
Co-Assembled Nanoparticles Comprising Sorafenib and Hederagenin Derivative for Enhanced Anti-Hepatic Fibrosis Activity Mingjun Lu, Ziqi Dai, Yixuan Lin, Changsheng Sun, Shuo Li, Zhuoqian Guo, Yongji Liu, Xiaobi Liu, Shanlan Li, Runping Liu, Bing Xu, Haimin Lei International Journal of Nanomedicine.2025; Volume 20: 9135. CrossRef
Global, Regional, and National Burden of Chronic Hepatitis B-Related Cirrhosis From 1990 to 2021 and Projections to 2050: A Finding From the Global Burden of Disease Study 2021 Jinyan Sun, Jin Guo Clinical and Translational Gastroenterology.2025; 16(10): e00890. CrossRef
Discovery of novel anti-fibrotics through phenotypic screening Alice R. Lapthorn, Sophie L. Harding-Fox, Kieran M. Feltham, Marcus M. Ilg, Selim Cellek Drug Discovery Today.2025; 30(9): 104450. CrossRef
Shining light on liquid–liquid phase separation in chronic liver disease Ming-Hui Li, Yang Yang, Qi-Qi Dong, Wen-Jie Sun, Hui Tao, Jing-Jing Yang Drug Discovery Today.2025; 30(10): 104464. CrossRef
Design, Synthesis,
and Evaluation of Antifibrotic
Activity of Nonsteroidal VDR Agonists Featuring 1,6-Naphthol as a
CD-Ring Surrogate Yi Gao, Yue Wu, Chun Guan, Nuo Cheng, Yu Tong, Cong Wang, Can Zhang Journal of Medicinal Chemistry.2025; 68(19): 20561. CrossRef
Sublingual Dripping Pill Formulation of Ganoderma amboinense Fruiting Body Extract Attenuates CCl4-Induced Liver Fibrosis via Multi-Pathway Regulation Chin-Feng Liu, Chong-Ming Pan, Chun-Lin Lee Current Issues in Molecular Biology.2025; 47(9): 697. CrossRef
Resveratrol ameliorates liver fibrosis by inhibiting ATF4 to regulate glutamine metabolism in hepatic stellate cells Huiya Ying, Yixiao Wang, Dandan Zhu, Jun Xu, Xiangting Zhang, Hong Pan, Yuan Zeng, Xiao Wu, Weimin Cai, Ruoru Zhou, Ziqiang Xia, Fujun Yu Archives of Pharmacal Research.2025; 48(11-12): 1420. CrossRef
Recent Progresses on Pathophysiology, Diagnosis, Therapeutic Modalities,
and Management of Non-alcoholic Fatty Liver Disorder Mahdi Barazesh, Sajad Jalili, Morteza Akhzari, Fouzieyeh Faraji, Ebrahim Khorramdin Current Drug Therapy.2024; 19(1): 20. CrossRef
An RORα agonist, ODH-08, inhibits fibrogenic activation of hepatic stellate cells via suppression of SMAD3 Haena Choi, Daehyun Oh, Hyeon-Ji Kim, Melody Chambugong, Mi-hyun Kim, Mi-Ock Lee, Hyeung-geun Park Life Sciences.2024; 340: 122443. CrossRef
TNFRSF12A mRNA Expression and Distribution of TNFRSF12A+ Cells in the Rate Liver during Thioacetamide-Induced Fibrogenesis E. I. Lebedeva, A. T. Shchastniy, A. S. Babenka Biology Bulletin.2024; 51(1): 11. CrossRef
RNA-seq combined network pharmacology reveals that Fu-Gan-Wan (FGW) inhibits liver fibrosis via NF-κB/CCL2/CCR2 and lipid peroxidation via Nrf2/HMOX1 signaling pathway Hanlin Shi, Xiaohong Duan, Jingcheng Dong, Yanyan Tao, Yang Lei Journal of Ethnopharmacology.2024; 326: 117963. CrossRef
Novel protein C6ORF120 promotes liver fibrosis by activating hepatic stellate cells through the PI3K/Akt/mTOR pathway Xin Wang, Hui Liu, Yuqi Wang, Peng Wang, Yunyun Yi, Yingying Lin, Xin Li Journal of Gastroenterology and Hepatology.2024; 39(7): 1422. CrossRef
The current landscape of antifibrotic therapy across different organs: A systematic approach Isabel Fuster-Martínez, Sara Calatayud Pharmacological Research.2024; 205: 107245. CrossRef
TNFRSF12A mRNA Expression and distribution of TNFRSF12A+ cells in rat liver during thioacetamide-induced fibrogenesis Elena I. Lebedeva, Anatoly T. Shchastniy, Andrei S. Babenka Известия Российской академии наук. Серия биологическая.2024; (1): 14. CrossRef
LOXL2 in non‐alcoholic Steatohepatitis (NASH): Insights into fibrosis pathogenesis and therapeutic potential Joys Rachel Immanuel, Rajnish Kumar, Ashish Kumar Agrahari, Shailendra Asthana Liver International Communications.2024;[Epub] CrossRef
Two-dimensional vascularized liver organoid on extracellular matrix with defined stiffness for modeling fibrotic and normal tissues Lei Ma, Lin Yin, Hai Zhu, Jing Li, Dong Wang Journal of Tissue Engineering.2024;[Epub] CrossRef
Phytotherapeutic approach to enhance the hepatoprotective activity of some edible plants: Molecular docking and nanoformulation Khaled A. Nematallah, Amgad Albohy, Noha Swilam Journal of Functional Foods.2024; 122: 106471. CrossRef
Advances in the understanding of the role and mechanism of action of PFKFB3‑mediated glycolysis in liver fibrosis (Review) Qian Liu, Jiajia Li, Xin Li, Li Zhang, Shun Yao, Yongfeng Wang, Biguang Tuo, Hai Jin International Journal of Molecular Medicine.2024;[Epub] CrossRef
Nitazoxanide mitigates methotrexate hepatotoxicity in rats: role in inhibiting apoptosis and regulating endoplasmic reticulum stress Nevertyty Mohamed Mahmoud, Shimaa M. Elshazly, Fatma El-shaarawy, Sawsan A. Zaitone, Afaf A. Aldahish, Gehan A. Ahmed, Manal S. Fawzy, Sheka Yagub Aloyouni, Sally Y. Abed, Tahani Saeedi, Shaimaa S. El-Sayed Frontiers in Pharmacology.2024;[Epub] CrossRef
Diagnostic Efficacy of Serum Asialo α1-Acid Glycoprotein Levels for Advanced Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Compared to That in Healthy Subjects: A Prospective Study Yoonseok Lee, Seryun Bae, Ji Hoon Kim, Minjung Kwak, So Yeon Jeon, Taehyung Kim, Sun Young Yim, Young-Sun Lee, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun Journal of Clinical Medicine.2023; 12(2): 712. CrossRef
Association between Cardiovascular Disease and Liver Disease, from a Clinically Pragmatic Perspective as a Cardiologist Mitsutaka Nakashima, Kazufumi Nakamura, Takahiro Nishihara, Keishi Ichikawa, Rie Nakayama, Yoichi Takaya, Norihisa Toh, Satoshi Akagi, Toru Miyoshi, Teiji Akagi, Hiroshi Ito Nutrients.2023; 15(3): 748. CrossRef
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials Jihyun An, Joo Hyun Sohn Clinical and Molecular Hepatology.2023; 29(Suppl): S268. CrossRef
Immune microenvironment changes of liver cirrhosis: emerging role of mesenchymal stromal cells Qiuyun Yi, Jinxian Yang, Ying Wu, Ying Wang, Qiqi Cao, Wen Wen Frontiers in Immunology.2023;[Epub] CrossRef
Hydronidone ameliorates liver fibrosis by inhibiting activation of hepatic stellate cells via Smad7‐mediated degradation of TGFβRI Xianjun Xu, Yuecheng Guo, Xin Luo, Zhenyang Shen, Zhongshang Sun, Bo Shen, Cui Zhou, Junjun Wang, Jingyi Lu, Qingqing Zhang, Yanping Ye, Ying Luo, Ying Qu, Xiaobo Cai, Hui Dong, Lungen Lu Liver International.2023; 43(11): 2523. CrossRef
Hepatoprotective Effect of Medicine Food Homology Flower Saffron against CCl4-Induced Liver Fibrosis in Mice via the Akt/HIF-1α/VEGF Signaling Pathway Huajuan Jiang, Xulong Huang, Jiaxin Wang, Yongfeng Zhou, Chaoxiang Ren, Tao Zhou, Jin Pei Molecules.2023; 28(21): 7238. CrossRef
Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches Omima S. Mohammed, Hany G. Attia, Bassim M. S. A. Mohamed, Marawan A. Elbaset, Hany M. Fayed Journal of Pharmacy & Pharmaceutical Sciences.2023;[Epub] CrossRef
A Unique Immune-Related Gene Signature Represents Advanced Liver Fibrosis and Reveals Potential Therapeutic Targets Pil-Soo Sung, Chang-Min Kim, Jung-Hoon Cha, Jin-Young Park, Yun-Suk Yu, Hee-Jung Wang, Jin-Kyeoung Kim, Si-Hyun Bae Biomedicines.2022; 10(1): 180. CrossRef
Stanniocalcin 1 is a serum biomarker and potential therapeutic target for HBV‐associated liver fibrosis Kristy Kwan‐Shuen Chan, Tsz‐Chun Hon, Kwan‐Yung Au, Hiu‐Lam Choi, Danny Ka‐Ho Wong, Albert Chi‐Yan Chan, Man‐Fung Yuen, Ching‐Lung Lai, Regina Cheuk‐Lam Lo The Journal of Pathology.2022; 257(2): 227. CrossRef
The Role of Macrophages in Liver Fibrosis: New Therapeutic Opportunities Eleonora Binatti, Alessio Gerussi, Donatella Barisani, Pietro Invernizzi International Journal of Molecular Sciences.2022; 23(12): 6649. CrossRef
Treatment of Liver Fibrosis: A 20-Year Bibliometric and Knowledge-Map Analysis Yun-Kai Dai, Zhi-Min Zhao, Chenghai Liu Frontiers in Pharmacology.2022;[Epub] CrossRef
The emerging roles of extracellular vesicles as intercellular messengers in liver physiology and pathology Youngseok Lee, Jong-Hoon Kim Clinical and Molecular Hepatology.2022; 28(4): 706. CrossRef
Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach Michael H. Le, Yee Hui Yeo, Biyao Zou, Scott Barnet, Linda Henry, Ramsey Cheung, Mindie H. Nguyen Clinical and Molecular Hepatology.2022; 28(4): 841. CrossRef
Multiplexed Digital Spatial Protein Profiling Reveals Distinct Phenotypes of Mononuclear Phagocytes in Livers with Advanced Fibrosis Jaejun Lee, Chang Min Kim, Jung Hoon Cha, Jin Young Park, Yun Suk Yu, Hee Jung Wang, Pil Soo Sung, Eun Sun Jung, Si Hyun Bae Cells.2022; 11(21): 3387. CrossRef
Hepatic HRC induces hepatocyte pyroptosis and HSCs activation via NLRP3/caspase-1 pathway Jingwen Wu, Mingyu Zhang, Suhong Xia, Ping Han, Kai Zhao, Kaixin Peng, Wangdong Zhou, Dean Tian, Jiazhi Liao, Jingmei Liu Journal of Molecular Medicine.2022; 100(12): 1787. CrossRef
Myofibroblast specific targeting approaches to improve fibrosis treatment Elfa Beaven, Raj Kumar, Himanshu N. Bhatt, Stephanie V. Esquivel, Md Nurunnabi Chemical Communications.2022; 58(98): 13556. CrossRef
Multiplexed Digital Spatial Protein Profiling Reveals a Unique Protein Signature for Advanced Liver Fibrosis Jaejun Lee, Chang Min Kim, Jung Hoon Cha, Jin Young Park, Yun Suk Yu, Hee Jung Wang, Pil Soo Sung, Eun Sun Jung, Si Hyun Bae SSRN Electronic Journal .2022;[Epub] CrossRef
Protective Effect of Oligonol on Dimethylnitrosamine-Induced Liver Fibrosis in Rats via the JNK/NF-κB and PI3K/Akt/Nrf2 Signaling Pathways Changyong Lee, Jeonghyeon Bak, Sik Yoon, Jeon-Ok Moon Antioxidants.2021; 10(3): 366. CrossRef
First
Prev
